None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E (2014) Cancer Med 3(3): 572-9
    › Primary publication · 24574334 (PubMed) · PMC4101748 (PubMed Central)
  2. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology (2014) Clin Colorectal Cancer 13(2): 100-9
    › Primary publication · 24512953 (PubMed) · PMC4019685 (PubMed Central)
  3. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. Chan E, Berlin J (2014) J Clin Oncol 32(6): 487-8
    › Primary publication · 24419124 (PubMed)
  4. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD (2011) Am J Clin Oncol 34(6): 581-6
    › Primary publication · 21217396 (PubMed) · PMC3133812 (PubMed Central)
  5. Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer. Chan E (2010) Clin Adv Hematol Oncol 8(1): 37-9
    › Primary publication · 20351681 (PubMed)
  6. Anal cancer: progress on combined-modality and organ preservation. Chan E, Kachnic LA, Thomas CR (2009) Curr Probl Cancer 33(5): 302-26
    › Primary publication · 20082844 (PubMed)
  7. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will? Chan E, Berlin JD (2007) Gastrointest Cancer Res 1(5): 204-6
    › Primary publication · 19262710 (PubMed) · PMC2632532 (PubMed Central)
  8. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD (2008) Am J Clin Oncol 31(5): 413-6
    › Primary publication · 18838875 (PubMed)
  9. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML (2008) Invest New Drugs 26(4): 339-45
    › Primary publication · 18463792 (PubMed)
  10. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) N Engl J Med 358(11): 1109-17
    › Primary publication · 18337601 (PubMed) · PMC2361129 (PubMed Central)
  11. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J (2008) Invest New Drugs 26(3): 241-7
    › Primary publication · 18217204 (PubMed)